scispace - formally typeset
L

Lanmei Chen

Researcher at Murdoch University

Publications -  10
Citations -  559

Lanmei Chen is an academic researcher from Murdoch University. The author has contributed to research in topics: DNA damage & Apoptosis. The author has an hindex of 5, co-authored 10 publications receiving 206 citations.

Papers
More filters
Journal ArticleDOI

Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics.

TL;DR: A panoramic view of current exosome isolation techniques is provided, providing perspectives toward the development of novel approaches for high-efficient exosomes isolation from various types of biological matrices.
Journal ArticleDOI

Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.

TL;DR: Antitumor mechanism studies show that Ru1 and Ru2 can cause cell cycle arrest in the G0/G1 phase by regulating cell cycle relative proteins and induce apoptosis through mitochondrial dysfunction, reactive oxygen species (ROS) accumulation and ROS-mediated DNA damage.
Journal ArticleDOI

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis.

TL;DR: In this paper, a comprehensive overview of aptamer-based lateral flow assay (LFA) design strategies is provided to facilitate researchers to develop optimised aptamerbased LFAs, including immobilization strategies, signalling methods, and target capturing approaches.
Journal ArticleDOI

Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase.

TL;DR: Three Ru(II) complexes with salicylate as ligand were synthesized and characterized and the anticancer effect exerted by them was evaluated, found to exhibit obvious anticancer activity, in comparison with cisplatin, against cancer cell lines, while displaying low toxicity to the normal cell line BEAS-2B.
Journal ArticleDOI

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex.

TL;DR: The results showed that ruthenium (II) methylimidazole complexes exhibited moderate antitumor activity comparable with cisplatin against A549, NCI-H460, MCF-7 and HepG2 human cancer cells, but with less toxicity to a human normal cell line HBE.